Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05171075 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
A Phase 3 study of Pulmonary Embolism and Venous Thromboembolism, sponsored by Anthos Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 417
- Enrollment target
- 20
- Study locations
NCT05171075: Active Phase 3 study of Pulmonary Embolism and Venous Thromboembolism, sponsored by Anthos Therapeutics.
NCT05171075 is a Phase 3 study of Pulmonary Embolism and Venous Thromboembolism that is active but no longer recruiting, run by Anthos Therapeutics. The registered enrollment target is 417 participants, below the 3,050-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05171075, a Phase 3 study of Pulmonary Embolism and Venous Thromboembolism, is active but no longer recruiting, sponsored by Anthos Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 417 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
Primary Outcome
Time to first adjudicated venous thromboembolism (VTE) event recurrence
Conditions Studied
Interventions
- BIOLOGICAL Abelacimab
- DRUG Dalteparin
Study Locations (20)
New York
- Memorial Sloan Kettering Cancer Center-Commack - Commack
- Memorial Sloan Kettering Cancer Center-West Harrison - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medical College - New York
Other
- LK Wiener Neustadt - Neustadt
- Medical University of Vienna - Vienna
- University of Calgary - Calgary
- Sault Area Hospital - Marie
Ontario
- Hamilton Health Sciences, Juravinski Hospital and Cancer Centre - Hamilton
- Ottawa Hospital Research Instituite - Ottawa
- Ottawa Hospital Research Instituite - Ottawa
New South Wales
- Blacktown Hospital - Blacktown
- Westmead Hospital - Westmead
District of Columbia
- Washington DC VAMC - Washington D.C.
Illinois
- NorthShore University Health System - Evanston
Missouri
- Barnes-Jewish Hospital - St Louis
New Jersey
- Memorial Sloan Kettering Cancer Center-Middletown - Middletown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2022-09-27 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 3 |
What the registry record for NCT05171075 still lists
NCT05171075 is an interventional study that assigns participants to a tested intervention. The registered 417 participants enrollment target is mid-sized for trials with a published cap, below the 3,050-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Pulmonary Embolism appearing as the primary indexed condition, and to 2 interventions - of which Abelacimab is the first listed.
NCT05171075 names 20 study sites across 11 states, led by New York, Other, Ontario.
Frequently Asked Questions
What is clinical trial NCT05171075 about?
NCT05171075 is a clinical study titled "A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE". This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
What is the current status of trial NCT05171075?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 417 participants. The study started on 2022-09-27. Estimated completion is 2027-02-28.
What conditions does trial NCT05171075 study?
This clinical trial studies the following conditions: Pulmonary Embolism, Venous Thromboembolism, Deep Venous Thrombosis.
What interventions are being tested in trial NCT05171075?
The interventions under investigation include: Abelacimab (BIOLOGICAL), Dalteparin (DRUG).
Who is sponsoring clinical trial NCT05171075?
This trial is sponsored by Anthos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05171075 being conducted?
This trial has 20 study locations across District of Columbia, Illinois, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Embolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05171075's enrollment target sits among peer trials
417 14th of 48 higher than 35 of 48 other Pulmonary Embolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Embolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
RECRUITING · Phase 3
-
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
COMPLETED · Phase 3
-
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
COMPLETED · Phase 3
-
A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI